$CURR Key operational highlights included the following:
Gross revenue of $1.6 million reflected an increase of 31.2% from Q1 to Q2 with further acceleration expected in Q3 and Q4.
Gross margins increased and we expect the high margin sales to accelerate with our new marketing initiatives.
SG&A expenses (excluding stock-based compensation) decreased by $3.4 million in the first half of 2022.
Cost reductions and operating leverage helped narrow operating loss by $1.0 million in 2022 (excluding non-cash stock valuation benefit in 2021), even before the July asset sale that will reduce our ongoing cash burn further.
Operational Highlights
Other operational highlights during the second quarter of 2022 and subsequent weeks included:
CURE announced that it sold a portion of its platform technology intellectual property and related assets in July 2022 for $20 million of non-dilutive capital in total consideration. A portion of the cash proceeds was used to pay down certain debt obligations and the balance will be used to grow the Company’s intellectual property portfolio and its wellness and beauty brands. The Company retained 15 of its patents and will continue to be an incubator for future technologies and patents. In addition, CURE intends to monetize the patents through the commercialization of the technology or through the licensing or sale of the technology.
CURE’s wholly-owned subsidiary The Sera Labs, also announced that four SKUs of its Seratopical Revolution skincare line with P3P, the proprietary delivery system, is now being sold at 1,372 Walmart Stores. Distribution in Walmart will be increasing to 1,800 stores in September with two additional items bringing the total to six SKU’s.
Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips™ on shelves at CVS, Amazon.com and Target.com. Nutri-Strips are proprietary to Sera Labs and are the result of years of research.
CURE announced positive findings from a study conducted at Cincinnati Children’s Hospital Medical Center (CCHMC) using CURE’s proprietary, single dose, oral, 40,000 IU vitamin D (branded ImmunD3™ Nutri-Strips™ in the retail wellness market) in pediatric patients before stem cell therapy. CURE’s oral vitamin D supplement was found to be more effective than standard supplementation in achieving pre- and post-surgery vitamin D sufficiency, which is critical for reducing immune-mediated organ damage in the children receiving HSCT.
Gross revenue of $1.6 million reflected an increase of 31.2% from Q1 to Q2 with further acceleration expected in Q3 and Q4.
Gross margins increased and we expect the high margin sales to accelerate with our new marketing initiatives.
SG&A expenses (excluding stock-based compensation) decreased by $3.4 million in the first half of 2022.
Cost reductions and operating leverage helped narrow operating loss by $1.0 million in 2022 (excluding non-cash stock valuation benefit in 2021), even before the July asset sale that will reduce our ongoing cash burn further.
Operational Highlights
Other operational highlights during the second quarter of 2022 and subsequent weeks included:
CURE announced that it sold a portion of its platform technology intellectual property and related assets in July 2022 for $20 million of non-dilutive capital in total consideration. A portion of the cash proceeds was used to pay down certain debt obligations and the balance will be used to grow the Company’s intellectual property portfolio and its wellness and beauty brands. The Company retained 15 of its patents and will continue to be an incubator for future technologies and patents. In addition, CURE intends to monetize the patents through the commercialization of the technology or through the licensing or sale of the technology.
CURE’s wholly-owned subsidiary The Sera Labs, also announced that four SKUs of its Seratopical Revolution skincare line with P3P, the proprietary delivery system, is now being sold at 1,372 Walmart Stores. Distribution in Walmart will be increasing to 1,800 stores in September with two additional items bringing the total to six SKU’s.
Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips™ on shelves at CVS, Amazon.com and Target.com. Nutri-Strips are proprietary to Sera Labs and are the result of years of research.
CURE announced positive findings from a study conducted at Cincinnati Children’s Hospital Medical Center (CCHMC) using CURE’s proprietary, single dose, oral, 40,000 IU vitamin D (branded ImmunD3™ Nutri-Strips™ in the retail wellness market) in pediatric patients before stem cell therapy. CURE’s oral vitamin D supplement was found to be more effective than standard supplementation in achieving pre- and post-surgery vitamin D sufficiency, which is critical for reducing immune-mediated organ damage in the children receiving HSCT.
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
